Faron’s Post

View organization page for Faron, graphic

4,575 followers

We are delighted to announce that #bexmarilimab, our wholly owned #immunotherapy candidate, has been granted Fast Track Designation (FTD) by the FDA for the treatment of relapsed or refractory myelodysplastic syndrome (r/r MDS) in combination with azacitidine.   Given the previously reported promising results in both Phase 1 and 2 of our BEXMAB trial when treating r/r MDS patients using a combination of bexmarilimab and azacitidine to overcome primary or developed resistance to azacitidine, bexmarilimab has been granted Fast Track Designation subsequent to the accelerated development plan proposed by the FDA in July.   This FTD further strengthens the bexmarilimab program by offering clinical development and commercialization benefits.   Read the full press release here https://lnkd.in/enWYY3tk   #Faron #Biotech #drugDevelopment 

  • No alternative text description for this image
Sami Miettinen

Partner at Translink, #neuvottelija and Board Member at Fredman Group

2mo

Well done sir! Hopefully Bexmarilimab will make the full phase shift!

Like
Reply
Doug Niven, PhD

Senior Advisor & Programme Leader | Drug Development and Commercialisation | Biopharma & Life Science Companies | Investors

2mo

This is excellent news, congratulations!!

Like
Reply
Ben Clauberg

Vice President Business Development Europe at AGC Biologics

2mo

Excellent news Juho! Well done! 👏

Like
Reply

This is exciting news Juho! Congratulations on this milestone.

Like
Reply
Amelia Elizabeth Rose

| Building a Global Talent Solutions Revolution | Executive Pharmaceutical Headhunter | Vector |

2mo

Congratulations Juho Jalkanen MD, PhD This is amazing news!!

Like
Reply
Pasi Sorvisto

Founder & Director at SPARK Finland, Director at SPARK Europe. Co-Founder of several companies.

2mo

Congrats Juho and the whole Faron team!

Cecilia Ahlin

Board certified medical oncologist consultant in early clinical development

2w

Congrats to the Faron team!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics